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Abstract: The accumulation of abnormal protein aggregates represents a universal hallmark of 
neurodegenerative diseases (NDDs). Post-translational modifications (PTMs) regulate protein 
structure and function. Dysregulated PTMs may influence the propensity for protein aggregation 
in NDD-proteinopathies. To investigate this, we systematically reviewed the literature to evaluate 
effects of PTMs on aggregation propensity for major proteins linked to the pathogenesis and/or 
progression of NDDs. A search of PubMed, MEDLINE, EMBASE, and Web of Science Core 
Collection was conducted to retrieve studies that investigated an association between PTMs and 
protein aggregation in seven NDDs: Alzheimer’s disease (AD), Parkinson’s disease (PD), 
Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxias, 
transmissible spongiform encephalopathy, and multiple sclerosis. Together, 1222 studies were 
identified, of which 69 met eligibility criteria. We identified that the following PTMs, in isolation or 
combination, potentially act as modulators of proteinopathy in NDDs: isoaspartate formation in Aβ, 
phosphorylation of Aβ or tau in AD; acetylation, 4-hydroxy-2-neonal modification, O-
GlcNAcylation or phosphorylation of α-synuclein in PD; acetylation or phosphorylation of TAR 
DNA-binding protein-43 in ALS, and SUMOylation of superoxide dismutase-1 in ALS; and 
phosphorylation of huntingtin in HD. The potential pharmacological manipulation of these 
aggregation-modulating PTMs represents an as-yet untapped source of therapy to treat NDDs.  
Keywords: neurodegenerative diseases; neurotoxicity; post-translational modifications; protein 
aggregates 
 
1. Introduction 
Neurodegenerative diseases (NDDs) are a major cause of global morbidity and mortality in the 
elderly, and, with an ever-rising prevalence, represent one of the greatest health challenges of the 
21st century. NDDs encompass heterogeneous cerebral proteinopathies, characterised by a 
progressive loss of vulnerable neurons such that patients present with broad clinical sequelae that 
includes motor, behavioural, and cognitive deficits [1–3]. At autopsy, NDDs can be characterised 
histopathologically via hallmark intra- or extracellular accumulations of degradation-resistant 
protein aggregates concentrated to certain brain regions (Table 1). These protein aggregates interfere 
with neuronal function, and presumably induce toxicity that ultimately drives cell death [2]. 
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Table 1. Overview of neuropathology, approximate global prevalence rates, and frequency of genetic 
and sporadic forms of major neurodegenerative diseases [3–29]. 
NDD 
Commonly 
Mutated 
Proteins 
Primary 
Region of 
Damage 
Compartment of 
Aggregate 
Deposition 
Aggregate-
Forming 
Proteins 
Global 
Prevalence 
Sporadic 
Cases 
Familial 
Cases 
AD APP, presenilins 
Cortex, 
hippocampu
s 
Extracellular, 
intracytoplasmic 
Aβ (plaques), 
tau (tangles) 593:100,000 >98% <2% 
PD α-synuclein, LRRK2 
Substantia 
nigra, cortex Intracytoplasmic 
α-synuclein 
(Lewy bodies) 1–2:1000 >90% <10% 
HD Htt 
Striatum, 
basal 
ganglia 
Intranuclear, 
intracytoplasmic Htt 1:10,000 3% 97% 
ALS 
TDP-43, 
SOD1, 
c9orf72 
Spinal motor 
neurons, 
motor cortex 
Intracytoplasmic SOD1, TDP-43 5:100,000 90–95% 5–10% 
MS - 
Basal 
ganglia, 
brainstem 
Intracytoplasmic, 
extracellular 
Aβ, tau, APP, 
bassoon 
protein 
30.1:100,000 80–90% 10–20% 
SCAs 
ATX1, 
ATX2, 
ATX3, 
CACNA1A, 
ATX7, TBP, 
ATN1 
Cerebellum, 
brainstem Intranuclear 
Atrophin-1, 
ataxins 3:100,000 No data No data 
TSEs PrP 
Cortex, 
brainstem, 
thalamus, 
cerebellum 
Extracellular PrP 1–2:1,000,000 85–90% 10–15% 
Abbreviations: APP, Amyloid precursor protein; LRRK2, Leucine-rich repeat kinase-2; Htt, 
Huntingtin; TDP-43, TAR DNA-binding protein 43; c9orf72, Chromosome 9 open reading frame 72; 
SOD1, Superoxide dismutase 1; ATX, ataxins; CACNA1A, Voltage-gated calcium channel subunit 
α1A; TBP, TATA-binding protein; ATN1, atrophin 1; PrP, Prion protein. 
Although the pathogenesis of Huntington’s disease (HD) and spinocerebellar ataxias (SCAs), as 
well as rare familial forms of other NDDs are influenced by gene mutations that affect protein 
structure and function, the majority of NDDs arise from a multifactorial idiopathic aetiology.  
Numerous drug therapies to treat NDDs have entered clinical trials over the last two decades, 
but their low success rates underscore substantial gaps in understanding of the molecular 
mechanisms that drive neurodegeneration in sporadic diseases [1–3]. Consequently, there are no 
specific curative treatments available to reverse or even halt the progression of brain pathology in 
NDDs, and all therapeutics licensed for treatment merely work at a symptomatic level. Furthermore, 
the number of patients with these age-related diseases is rising due to increased longevity, and this 
carries an enormous social and economic global burden. It is therefore crucial to elucidate the 
molecular mechanisms that trigger protein aggregation and subsequent neurotoxicity in order to 
identify potential targets for drug development, to resist or possibly reverse disease progression.  
1.1. Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common NDD and accounts for 60–80% of all cases of 
dementia [27,30]. More than 30 million people are currently suffering from AD, and this number is 
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estimated to increase to 115 million by 2050 [31]. Clinically, patients predominantly present with a 
decline in cognitive function that initially manifests as episodic short-term memory loss, but as the 
disease progresses, visuospatial, behavioural, and psychiatric disturbances follow and eventually 
lead to the inability to perform activities of daily living [32]. Diagnosing AD relies heavily on patient 
history and cognitive function tests such as the Mini Mental State Examination or the Montreal 
Cognitive Assessment, but screening for plasma and CSF biomarkers and brain imaging have proven 
helpful ancillary methods [1,33]. Nevertheless, macroscopic confirmation of AD is provided from 
post-mortem examination, and typified by widespread cortical atrophy primarily within the 
frontotemporal lobes (including the hippocampus) that leads to an enlargement of the lateral 
ventricles [1,2,34]. Microscopically, AD pathology is characterised by extracellular plaque deposits of 
aggregated amyloid-beta peptide (Aβ) as well as intracellular neurofibrillary tangles (NFTs) 
primarily composed of hyperphosphorylated fibrils of microtubule-associated protein tau [2,34]. 
Aβ peptide is primarily composed of 42–43 amino acids formed from proteolytic cleavage of the 
transmembranous amyloid precursor protein (APP) [34,35]. Two proteases that act on APP, a β-
secretase and γ-secretase, yield the Aβ40 and Aβ42 isoforms, respectively. Alternatively, APP may be 
processed by α-secretase via the non-amyloidogenic pathway [35–37]. While Aβ is believed to play a 
number of physiological roles, including regulation of synaptic activity [36,37], in AD, it acquires a 
toxic gain-of-function, undergoes oligomerisation and aggregation, eventually forming insoluble, 
fibrillar, senile plaques that are central to neurotoxicity and neurodegeneration [2,38,39].  
Human tau protein exists in six isoforms of between 352 and 441 amino acids encoded by the 
MAPT gene on chromosome 17q21.31. It is localised predominantly to neuronal axons, where its 
primary function is the stabilisation of microtubules and regulation of neuronal transport [40–42]. In 
AD, abnormally phosphorylated tau adopts an altered conformation that hinders its binding to 
microtubules and promotes its self-assembly (aggregation) into paired helical filaments (PHFs), the 
primary component of NFTs [40–42]. It is these tau aggregates and Aβ aggregates that have been the 
subject of targeted therapies [42]. 
1.2. Parkinson’s Disease 
Approximately 1% of individuals over the age of 60 years and close to 5% of the population aged 
80 or older suffer from Parkinson’s disease (PD), the second most common NDD and most common 
movement disorder [43]. PD is characterised by a progressive loss of dopaminergic neurons in the 
subcortical basal ganglia; specifically, within the substantia nigra pars compacta (SNpc) [1,2,43–45]. 
Since this midbrain region plays a crucial role in fine-tuning motor circuits and facilitating 
movement, PD manifests clinically with a pathognomonic triad of bradykinesia, rigidity, and resting 
tremor [1,45]. In addition to nigral degeneration, the primary pathological feature of PD is the 
presence of intraneuronal proteinaceous inclusions termed Lewy bodies (LBs), primarily composed 
of α-synuclein [2,46,47]. 
α-synuclein is a cytosolic 140 amino acid protein encoded by the SNCA gene on chromosome 
4q21. Although widely expressed within neurons, it is abundant at presynaptic terminals, indicative 
of a role in synaptic signalling. A number of rare SNCA point mutations trigger dominant familial 
(early-onset) forms of PD. Fibrillar forms of α-synuclein have been identified within LBs that 
accumulate in hereditary and sporadic forms of PD [46–49]. Oligomeric and/or fibrillar aggregates of 
α-synuclein may be cytotoxic and trigger neuronal degeneration. 
1.3. Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is a fatal, incurable NDD characterised by the loss of upper 
and lower motor neurons. ALS typically presents with symptoms of bulbar and spinal dysfunction 
including muscle weakness, wasting and spasticity, and ultimately, patients may become paralysed 
and die from respiratory failure [2,50,51]. Pathologically, both sporadic and familial ALS are 
characterised by marked cytoplasmic protein aggregates in degenerating neurons that harbour 
ubiquitinated forms of Trans-activation response DNA-binding protein 43 (TDP-43) and the 
antioxidant enzyme, superoxide dismutase 1 (SOD1) [10,50,51].  
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TDP-43 is a 414 amino acid protein encoded by the TARDBP gene on chromosome 1 and is 
normally nuclear resident and involved in the regulation of RNA metabolism. In ALS, cytoplasmic, 
ubiquitinated, hyperphosphorylated, and truncated forms of TDP-43 accumulate as protein 
aggregates [52–54]. These cytoplasmic aggregates are neurotoxic, produce ALS-like phenotypes, and 
contribute to a loss of nuclear (functional) TDP-43 [52–55]. 
Superoxide dismutase 1 (SOD1) is a 153-amino acid copper- and zinc-dependent metalloenzyme 
encoded by the SOD1 gene on chromosome 21q22.11. SOD1 functions to scavenge highly reactive 
superoxide radicals by catalysing their conversion to hydrogen peroxide and molecular oxygen [56]. 
SOD1 is predominantly cytoplasmic, although nuclear, lysosomal, and mitochondrial residences 
have also been reported [57]. In SOD1-mediated familial ALS, mutations in the SOD1 gene sequence 
are thought to affect post-translational processing, rendering the protein prone to misfolding, 
aggregation, and formation of neuronal inclusion bodies. Misfolded SOD1 is also found in 
cytoplasmic inclusions in patients with sporadic ALS, as well as other proteins including TDP-43 [58]; 
suggesting a common pathophysiological mechanism for hereditary and idiopathic ALS.  
1.4. Huntington’s Disease 
Huntington’s disease (HD) is a rare, autosomal dominant NDD with an average age of onset of 
40 years [59]. HD is caused by an expansion of the CAG repeat (≥36) in the Huntingtin (Htt) gene on 
chromosome 4p16.3, that when translated produces an elongated polyglutamine (polyQ) stretch in 
the Htt protein [59]. The formation of aggregated Htt within neuronal intranuclear inclusion bodies 
is a histopathological hallmark of HD [60]. Additionally, the degeneration of GABAergic medium 
spiny neurons in the striatum that project to other regions of the basal ganglia and thereby modulate 
central motor circuitries, is central to HD pathology [61]. This is reflected in the clinical picture of HD 
such that patients present with severe motoric abnormalities including prominent ‘dance-like’ 
involuntary movements termed chorea [62]. With disease progression, other brain regions undergo 
degeneration, with an associated array of additional psychiatric, behavioural, and cognitive 
symptoms. 
Htt is a large, 3144-amino acid, monomeric protein required for embryonic neurogenesis that 
controls a number of nuclear and cytoplasmic homeostatic functions including regulation of synaptic 
activity [63,64]. In HD, the expanded polyQ stretch of the protein induces production of N-terminal 
Htt fragments that are prone to misfold and form amyloid-like structures [65–68]. Furthermore, 
polyQ tracts have a tendency to form β-pleated sheets and this conformational change directly 
increases the aggregation propensity of Htt [66–68]. These changes result in the assembly of 
oligomeric structures and eventually the formation of Htt-positive intracellular inclusion bodies that 
disrupt cellular homeostasis and cause neuronal degeneration [69]. 
1.5. Spinocerebellar Ataxias 
Spinocerebellar ataxias (SCAs) are a heterogeneous group of >27 different autosomal dominant 
NDDs that share the phenotypical core feature of ataxia and are characterized by degenerative and 
atrophic changes in the central nervous system, primarily affecting the cerebellum [70]. The most 
common SCAs belong to the polyQ repeat diseases and are caused by CAG expansion mutations in 
a number of different genes [71].  
1.6. Transmissible Spongiform Encephalopathy 
Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, are 
progressive NDDs that typically present with variable symptomology including dementia and ataxia 
[72]. They can be classified according to their genetic, acquired, and sporadic aetiology, with the most 
common TSE being sporadic Creutzfeldt-Jakob disease [23]. TSEs typically present with a pathology 
that involves neuronal vacuolation (spongiform change), widespread neuronal death, and 
subsequent gliotic scarring in cerebral grey matter secondary to the accumulation of aberrant, self-
propagating prion protein scrapie (PrPsc) [73]. Diagnostic criteria as well as ancillary tests such as 
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electroencephalography or genetic testing facilitate diagnosis, but only at autopsy can a definitive 
diagnosis be confirmed [74]. Due to the propagating nature of TSEs and lack of disease-modifying or 
curative treatments, after clinical onset, the disease course is usually short with a median survival of 
5 months [75]. 
The prion gene PRNP on chromosome 20 encodes a human prion glycoprotein, PrPc, of 253 
amino acids localised to pre- and postsynaptic terminals in the CNS [76–78]. Its precise physiological 
function has been debated and is considered non-essential [79]: indicative that a toxic gain-of-
function rather than loss-of-function of PrPc underlies neurotoxicity in prion diseases [80]. In TSEs, 
PrPc misfolds and is partially converted from an α-helical to β-sheet structure that is resistant to 
proteolytic clearance, PrPsc [78,81]. Misfolded PrPsc accumulates in synaptic and axonal processes and 
forms fibrillar aggregates that are capable of inducing neuronal apoptosis in vitro and in vivo [80,82]. 
Pathology is thought to be propagated when abnormal PrPsc converts normal PrPc into PrPsc via an 
autocatalytic mechanism [83]. 
1.7. Multiple Sclerosis 
Multiple Sclerosis (MS) is traditionally classed as a neuroinflammatory disease caused by 
autoimmune-mediated axonal demyelination within the CNS [84,85]. Clinical presentation is variable 
since focal inflammatory lesions may affect any CNS structure, and the diagnostic process is therefore 
based on a combination of clinical history and examination, brain imaging, and blood screening [84]. 
There are four MS subtypes: relapsing remitting (RRMS), progressive relapsing (PRMS), primary 
progressive (PPMS) and secondary progressive (SPMS), and each has a unique therapeutic approach 
and prognosis [84,85]. 
While most subjects (≈85%) are diagnosed with RRMS at symptomatic onset, the majority of 
patients will progress to development of highly debilitating SPMS [85]. Post-mortem analyses of MS 
patients have demonstrated degenerative lesions and significant cerebral atrophy indicative of a 
NDD. Furthermore, the identification of proteinaceous, oligomeric aggregates, that include Aβ, tau, 
and APP, as well as deposits in neuronal somata composed of aggregated bassoon (Bsn) protein, may 
represent a link between neuroinflammation and neurodegeneration in MS [8,12,13]. 
Bsn is a large, 3926 amino acid, scaffold protein that is part of the presynaptic cytoskeletal matrix, 
and has multiple roles in mediating synaptic function [12,86]. In MS, Bsn is mis-localised and 
accumulates in neuronal cells, to induce neurotoxicity and neurodegeneration [12]. 
1.8. Protein Aggregation in Neurodegeneration 
Protein misfolding and accumulation of toxic aggregates has emerged as a central theme of 
paradigmatic NDDs [87]. Protein turnover is an orchestrated process controlled via a balance of 
protein synthesis and degradation. Cells are equipped with efficient protein quality control 
mechanisms such as the ubiquitin-proteasome system and chaperone-mediated autophagy that are 
able to eliminate aberrant or misfolded proteins [87,88]. However, the capacity or indeed fidelity of 
these degradative pathways may be compromised with a corresponding accumulation of damaged, 
misfolded, or aggregated proteins, and associated pathology. Hence the formation of protein 
aggregates may serve as an initiating step in cellular dysfunction in NDDs, and it is therefore critical 
to understand the molecular mechanisms that alter the protein aggregation of these NDD-associated 
proteins.  
1.9. Post-Translational Modifications and NDDs 
The chemical modifications of proteins during or after their biosynthesis via the covalent 
attachment of functional groups or proteolytic cleavage at specific amino acids are collectively termed 
protein post-translational modifications (PTMs). PTMs can be mediated by enzymatic or non-
enzymatic means and may be reversible or irreversible. Over 600 different PTMs have been 
demonstrated experimentally [89]. This plethora of PTMs diversifies the proteome by modulating the 
structural and functional properties of proteins. Due to their pivotal role in regulating cellular 
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processes and roles in ageing, protein PTMs may need to be strictly controlled, such that 
dysregulation of PTMs could contribute to disease pathogenesis or progression [90,91]. 
The major risk factor for developing NDD is age, and this may also correlate with disturbed 
PTM homeostasis. One could hypothesise that as an individual ages the likelihood of dysregulation 
of PTMs increases, and if this leads to aberrant modification of susceptible proteins then protein 
misfolding and aggregation, neurotoxicity, and ultimately neurodegeneration may ensue. Against 
this backdrop, the identification of the PTMs that drive dysregulated protein function proffer a 
therapeutic window if the formation of toxic protein aggregates could be obviated. Indeed, recent 
animal studies have demonstrated that therapies that influence protein PTMs provide a viable means 
to modulate proteinopathy and associated neurodegeneration [91,92]. 
The aim of this systematic research was to provide a comprehensive, unbiased analysis of the 
PTMs that have been reported to affect the aggregation propensity of proteins implicated in the 
pathology of AD, PD, ALS, HD, SCAs, TSEs, and MS. Mapping of the patterns and number of studies 
demonstrating aggregation-modulating PTMs will improve our understanding of the extent and site-
specificity of aggregation-inducing PTMs, and thereby provide an insight into novel therapeutic 
targets that may limit pathogenesis and/or disease progression. 
2. Methods 
A systematic review of the literature was carried out according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA). 
2.1. Search Strategy 
From the 7th to 17th September 2019, a systematic electronic database search was conducted on 
MEDLINE (OvidSP), EMBASE (OvidSP), Web of Science Core Collection, and PubMed to retrieve all 
experimental studies investigating the effect of PTMs on protein aggregation in the pre-specified 
NDDs. A combination of controlled vocabulary (MeSH) and free-text keywords were used for each 
of the four concepts and search terms included: (a) neurodegenerative diseases, nerve degeneration, 
neurodegenerat *, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, 
Huntington’s disease, spinocerebellar ataxia, transmissible spongiform encephalopathy, and 
multiple sclerosis; (b) protein aggregation, aggreg *; (c) beta-amyloid, tau, alpha-synuclein, TDP-43, 
superoxide dismutase 1, huntingtin, prions, protein aggregate, inclusion bodies; (d) post-
translational modifications, protein processing. The full search strategy for MEDLINE is provided as 
Supplementary Data S1. Additional studies were identified through bibliography screening of 
relevant review articles and hand-searching of relevant articles. 
2.2. Eligibility Criteria 
All search results (n = 1222) were exported into Endnote (Clarivate Analytics) and Excel 
(Microsoft) for duplicate removal (automatic deduplication and manual checking) and title/abstract 
screening to identify studies deemed appropriate to the pre-specified inclusion criteria. Included 
articles were original studies directly investigating the effect of PTMs at residues of human proteins 
central to pathology in AD, PD, ALS, HD, SCAs, TSEs, or MS for which the PTM had an effect on 
aggregation behaviour. Studies were excluded if they focused on proteins or NDDs other than those 
pre-defined, or were published in a language other than English, or performed with non-human 
proteins or tissue, or were review articles, editorials, or conference abstracts. 
2.3. Data Acquisition and Analysis 
Eligible publications were read in full and information for the following variables collated as a 
data extraction spreadsheet: NDD; protein investigated; type of PTM; site of PTM; peptide or protein 
source; in vitro or in vivo study; assay method for aggregation; overall study findings and conclusion; 
authors and year of publication. 
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3. Results 
A total of 1196 articles were identified from the database search and an additional 26 potentially 
relevant papers yielded from hand-searching key papers. Duplicate articles were removed, and then 
166 papers excluded based upon title screening, yielding 804 papers for abstract review. Further 
screening led to the exclusion of 662 articles and left a final 142 papers for full-text assessment. Of 
these, 73 studies did not meet the pre-defined eligibility criteria and were rejected based on the 
following grounds: off-topic (n = 37), full-text not accessible (n = 3), conference abstract (n = 2), review 
article (n = 6), focus on condition/protein not pre-specified in the inclusion criteria (n = 5), animal 
model (n = 5), lack of specificity (n = 15). The remaining 69 articles fulfilled the inclusion criteria and 
were included in the final analysis (Figure 1). 
Of the 69 included studies, the majority were focused upon PTMs and protein aggregation in 
AD (n = 28) and then PD (n = 20), 10 studies considered ALS, 7 HD, and 2 studies each examined 
SCAs and TSEs, respectively. No studies investigating the effect of PTMs on protein aggregation in 
the context of MS were identified from this search. The most commonly employed method to assess 
aggregation behaviour was Thioflavin T (ThT) fluorescence for quantitation of in vitro formation of 
amyloid-like fibrils [93]. Other studies that examined aggregation included the use of Western 
blotting, immunohistochemistry, sedimentation assays, atomic force microscopy, and transmission 
electron microscopy. The results for each NDD-related protein are presented and stratified according 
to effects on: (1) aggregation in general; (2) formation of oligomeric species; (3) formation of fibrillar 
aggregates; and (4) formation of amorphous aggregates.  
 
Figure 1. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow chart 
detailing the stages of study retrieval and selection [94]. 
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3.1. Alzheimer’s Disease 
3.1.1. Aβ PTMs and Propensity for Aggregation 
Eleven studies focused upon aggregation behaviour of Aβ. Two studies investigated 
isoaspartate modification (collectively covering residues D1, D7, and D23) and both reported that it 
had a pro-aggregation effect, with enhanced formation of Aβ oligomers as well as fibrillar aggregates 
[95,96]. A similar pro-aggregation effect was observed after N-terminal pyroglutamylation at E3 of 
Aβ [97]. The effect of phosphorylation on aggregation propensity of Aβ varied for different residues: 
specifically, S8 phosphorylation increased the formation of oligomeric and high molecular weight 
species [98,99], while phosphorylation at S26 had an overall inhibitory effect on the formation of large 
aggregates through stabilising intermediate oligomers [100]. Reduced transition from oligomer to 
fibril was also observed for N-homocysteinylation at K16 and K28 [101]. The results relating to 
nitration at Y10 were inconclusive: two studies reported a decrease of Aβ aggregation propensity 
[102,103], whereas one study reported a pro-aggregation effect [104]. Lastly, glycation at R5 and K16 
reduced the formation of fibrillar aggregates [105]. A detailed overview of the effect of each PTM on 
the aggregation behaviour of Aβ is presented in Table 2. 
Interestingly, all PTMs that affected Aβ aggregation were within the first 28 residues of the 
peptide (Figure 2), leaving the 29–40 C-terminal section less prone to structural alterations. 
Table 2. Summary of β-amyloid PTMs and propensity for protein aggregation. 
Post-Translational 
Modification 
Residues 
Modified 
Author & 
Year Aggregation 
Formation 
of 
Oligomers 
Formation 
of Fibrillar 
Aggregates 
Formation 
of 
Amorphous 
Aggregates 
Glycation R5, K16 
Emendato 
et al., 2018 
[105] 
Decrease - Decrease - 
Isoaspartate 
formation D23 
Shimizu et 
al., 2002 
[96] 
Increase - Increase - 
 D1, D7, 
D23 
Fossati et 
al., 2013 
[95] 
Increase Increase Increase - 
N-
Homocysteinylation 
K16, K28 
Khodadadi 
et al., 2012 
[101] 
Decrease Increase Decrease - 
N-terminal 
pyroglutamylation  
N-
terminal 
E3 
Schilling et 
al., 2006 
[97] 
Increase Increase Increase - 
Nitration Y10 
Kummer et 
al., 2011 
[104] 
Increase Increase Increase - 
 Y10 
Zhao et al., 
2015 [102] Decrease Decrease Decrease - 
 Y10 
Guivernau 
et al., 2016 
[103] 
Decrease Increase Decrease - 
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Phosphorylation S8 
Jamasbi et 
al., 2017 
[98] 
Increase - Increase - 
 S8 
Kumar et 
al., 2011 
[99] 
Increase Increase Increase - 
 
S26 
Kumar et 
al., 2016 
[100] 
Decrease Increase Decrease - 
 
Figure 2. Schematic representation of beta-amyloid-42 peptide illustrating PTMs and respective 
amino acid residues. 
3.1.2. Tau PTMs and Propensity for Aggregation 
The majority of studies that have investigated PTMs of tau and protein aggregation have focused 
upon acetylation. Collectively, the results of acetylation analyses have been equivocal; with a 
demonstration of increased aggregation after acetylation at K280/K281 [106–108], but with acetylation 
at multiple lysine residues, including K280/281, also reported to decrease aggregation and the 
fibrillation rate of tau [109,110]. Furthermore, K321 acetylation alone or in combination with 
acetylation at other lysine residues decreased the level of tau aggregates [110,111]. 
Carbamylation, C-terminal truncation, glycation, proteolytic cleavage, pseudo-phosphorylation 
(replacement of a phospho-acceptor amino acid with a negatively charged amino acid to mimic 
phosphorylation), and SUMOylation all primarily increased tau assembly into aggregates [112–118], 
with the exception of pseudo-phosphorylation at S235 that significantly reduced tau aggregation 
[116]. O-GlcNAcylation, S-guanylation, and methylation decreased aggregation [119–121]. Likewise, 
site-specific tau nitration at Y18 and Y394 resulted in the formation of fewer and/or shorter tau 
filaments compared to the unmodified protein [122]. The effect of phosphorylation of tau and 
aggregation varied for different isoforms: phosphorylation of 4R2N and 3R1N at specific residues 
increased tau aggregation, while phosphorylation of 4R0N and 3R2N tau isoforms decreased their 
aggregation [114]. Additionally, one study identified an ‘acetylation-phosphorylation switch’, 
whereby acetylation of K321 was able to prevent phosphorylation at S324, a common PTM observed 
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in tau inclusions in patients with AD [111]. A summary of the PTMs of tau that influence aggregation 
propensity are included as Table 3, and Figure 3. 
Table 3. Summary of Tau PTMs and propensity for protein aggregation. 
Post-
Translational 
Modification 
Isoform and 
Residues 
Modified 
Author & 
Year Aggregation 
Formation 
of 
Oligomers 
Formation 
of Fibrillar 
Aggregates 
Formation of 
Amorphous 
Aggregates 
Acetylation 4R2N: 
K280/K281 
Trzeciakie
wicz et al., 
2017 [106] 
Increase - Increase - 
 
4R2N: 
K163/K174/K
190/K224/K2
34/K240/K25
4/K280/K281
/K290/K311/
K375/K385/K
395 
Ferreon et 
al., 2018 
[109] 
Decrease - Decrease - 
 
4R0N: K321, 
K259/K290/K
321/K353, 
K290/K321, 
K274 
Carlomagn
o et al., 
2017 [111] 
Decrease - Decrease - 
 
4R2N: K163, 
K174, K224, 
K225, K234, 
K240, K259, 
K274, K280, 
K290/K321, 
K294, K298, 
K317, K353, 
K369 
Kamah et 
al., 2014 
[110] 
Decrease - Decrease - 
 4R2N: K280 
Haj-Yahya 
and 
Lashuel, 
2018 [107] 
Increase Increase Decrease - 
 
4R, Tau-K18: 
K163/K280/K
281/K369 
Cohen et 
al., 2011 
[108] 
Increase - Increase - 
Carbamylation 
4R2N: K311, 
K280, 
K311/K280 
KrishnaKu
mar et al., 
2018 [112] 
Increase - Increase - 
C-terminal 
Truncation 
4R2N: D421, 
E391 
Yin and 
Kuret, 2006 
[113] 
Increase - Increase - 
Glycation 
4R2N: K67, 
K148, K163, 
K180, K190, 
K259, K267, 
Liu et al., 
2016 [114] 
Increase - Increase - 
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K274, K281, 
K290, K298, 
K311, K317, 
K321, K331, 
K340, K343, 
K353, K369, 
K370, K375, 
K383, K385, 
K395 
 
3R2N: K24, 
K163, K174, 
K180, K190, 
K254, K259, 
K267, K311, 
K343, K353, 
K369, K385 
Liu et al., 
2016 [114] 
Increase - Increase - 
Methylation 
4R2N: 
Muliple 
residues* 
Funk et al., 
2014 [121] Decrease - Decrease - 
Nitration 4R2N: Y18, 
Y394 
Reynolds 
et al., 2005 
[122] 
Decrease - Decrease - 
O-
GlcNAcylation 
4R2N: S400 
Yuzwa et 
al., 2014 
[119] 
Decrease - Decrease - 
Phosphorylation 
4R2N: S68, 
T169, S214, 
S262, S285, 
S319, S356, 
T403 
Liu et al., 
2016 [114] 
Increase - Increase - 
 3R1N: T71 Liu et al., 
2016 [114] 
Increase - Increase - 
 
4R0N: T111, 
S198, S214, 
S237, S238, 
S241, S258, 
S324, S352, 
S356, S400, 
S404 
Liu et al., 
2016 [114] Decrease - Decrease - 
 3R2N: S235, 
S237, S324 
Liu et al., 
2016 [114] 
Decrease - Decrease - 
Proteolytic 
cleavage 
4R2N: D421 
Mead et 
al., 2016 
[115] 
Increase - - Increase 
Pseudo-
phosphorylation 
4R2N: S199, 
S199/S202/T2
05, T212, 
S214, 
Necula and 
Kuret, 2004 
[116] 
Increase - Increase - 
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T212/S214, 
S396/S404,  
 4R2N: S235 
Necula and 
Kuret, 2004 
[116] 
Decrease - Decrease - 
 4R2N: T212 
Chang et 
al., 2011 
[117] 
Increase - Increase - 
S-Guanylation 3R2N: C291 
Yoshitake 
et al., 2016 
[120] 
Decrease Decrease Decrease - 
 
4R2N: C291, 
C322 
Yoshitake 
et al., 2016 
[120] 
Decrease Decrease Decrease - 
SUMOylation 4R2N: K340 Luo et al., 
2014 [118] 
Increase - - - 
* Tau methylation at multiple residues across the protein. 
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Figure 3. Schematic representation of tau protein illustrating PTMs and respective amino acid 
residues. 
3.2. Parkinson’s Disease 
α-Synuclein PTMs and Propensity for Aggregation 
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Twenty studies investigated the effects of PTMs on the PD-related protein, α-synuclein. 
Collectively, acetylation of the N-terminal region of α-synuclein reduced aggregation in four out of 
five studies [123–126], and with one study that reported that this PTM increased the propensity of α-
synuclein to aggregate [127]. Adenylylation at T33, T54, and T75 reduced α-synuclein aggregation 
[128]. Glycation at multiple lysine residues increased α-synuclein aggregation and formation of stable 
oligomers [129]. Increased oligomerization but reduced aggregation was triggered after 
SUMOylation at K96 and K102 [130]. 4-hydroxy-2-neonal (HNE) modification at H50 resulted in 
enhanced formation of oligomers, which in two studies reduced the formation of fibrillar aggregates 
[131–133]. O-GlcNAcylation decreased formation of aggregates, and favoured the formation of 
oligomers after modification at T81 and S87, or when O-GlcNAcylation was performed across the 
whole protein [134,135]. By contrast, α-synuclein O-GlcNAcylated at T72 formed markedly fewer 
oligomers compared to the non-modified protein [136]. O-GlcNAcylation at T72 also inhibited S129 
phosphorylation [136]; a PTM that increased the formation of α-synuclein aggregates [137,138]. 
Lastly, nitration of α-synuclein displayed conflicting results regarding effects upon α-synuclein 
aggregation [131,139–142]. Although all of these studies demonstrated that nitration increased 
oligomerisation, this was associated with a reduction or inability to form fibrils [131,139,141]. A 
summary of the PTMs that influence aggregation propensity of α-synuclein are shown in Table 4. 
Table 4. Summary of α-synuclein PTMs and propensity for protein aggregation. 
Post-
Translational 
Modification 
Residues 
Modified 
Author & 
Year 
Aggregation 
Formation 
of 
Oligomers 
Formation 
of Fibrillar 
Aggregates 
Formation of 
Amorphous 
Aggregates 
Acetylation N-
terminus 
Bartels et al., 
2014 [123] 
Decrease - Decrease - 
 
N-
terminus 
Kang et al., 
2012 [124] Decrease - Decrease - 
 N- 
terminus 
Bu et al., 
2017 [125] 
Decrease Decrease Decrease - 
 
N-
terminus 
Birol et al., 
2019 [127] Increase - Increase - 
 
N-
terminus, 
K6, K10 
Oliveira et 
al., 2017 
[126] 
Decrease Decrease Decrease - 
Adenylylation 
T33, T54, 
T75 
Sanyal et al., 
2019 [128] 
Decrease - Decrease - 
Glycation 
K6, K10, 
K12, K21, 
K23, K32, 
K34, K43, 
K45 
Vicente et 
al., 2017 
[129] 
Increase Increase Decrease Increase 
4-Hydroxy-2-
neonal 
Modification 
H50, and 
other Lys 
residues 
Qin et al., 
2006 [133] 
Decrease Increase Decrease - 
 
H50, and 
other Lys 
residues 
Xiang et al., 
2013 [131] 
Decrease Increase Decrease - 
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 H50 
Xiang et al., 
2015 [132] - Increase - - 
Nitration 
Y39, Y125, 
Y133/Y136 
Burai et al., 
2015 [139] 
Decrease Increase Decrease Increase 
 
Y39, Y125, 
Y133, Y136 
Liu et al., 
2011 [140] - Increase - Increase 
 
Y39, Y125, 
Y133, Y136 
Hodara et 
al., 2004 
[141] 
Increase - - - 
 
Y39, Y125, 
Y133, Y136 
Souza et al., 
2000 [142] Increase Increase - - 
 Y39/Y125/
Y133/136 
Xiang et al., 
2013 [131] 
Decrease Increase Decrease - 
O-
GlcNAcylation 
T72 
Levine et al., 
2019 [134] 
Decrease - Decrease - 
 T75 Levine et al., 
2019 [134] 
Decrease - Decrease - 
 T81 
Levine et al., 
2019 [134] 
Decrease Increase Decrease - 
 S87 
Levine et al., 
2019 [134] Decrease Increase Decrease - 
 
T72/T75/T8
1 
Levine et al., 
2019 [134] 
Decrease - Decrease - 
 
Muliple 
sites * 
Zhang et al., 
2017 [135] Decrease Increase Decrease - 
 T72 
Marotta et 
al., 2015 
[136] 
Decrease Decrease Decrease - 
Phosphorylation S129 
Fujiwara et 
al., 2002 
[137] 
Increase Increase Increase - 
 S129 
Samuel et al., 
2016 [138] Increase - Increase - 
SUMOylation K96, K102 
Krumova et 
al., 2011 
[130] 
Decrease Increase Decrease - 
* α-synuclein O-GlcNAcylation at multiple residues across the entire protein was investigated. 
Aggregation-related modifications of α-synuclein cluster to discrete regions of the protein, 
dependent upon the type of PTM (Figure 4). More specifically, acetylation, glycation, and HNE 
modifications were confined to the N-terminal region, O-GlcNAcylation targeted the NAC region, 
and SUMOylation, phosphorylation, and nitration were predominantly at the C-terminal region. 
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Figure 4. Schematic representation of α-synuclein illustrating PTMs and respective amino acid 
residues. 
3.3. ALS 
3.3.1. TAR DNA-Binding Protein 43 PTMs and Propensity for Aggregation 
Acetylation of K145 and K192 increased aggregation of TDP-43 [143,144]. C-terminal 
fragmentation at D89 and D219 produced aggregation-prone TDP-43 fragments (residues 90–414 or 
residues 220–414, respectively) [145]. Phosphorylation of TDP-43 was detected at multiple sites, 
including S409/S410, and increased TDP-43 aggregation in two studies [146,147], but decreased the 
aggregation of C-terminal fragments of TDP-43 [148]. Phosphorylation at multiple serine residues 
(including S409 and S410) also induced a protective (reduction of aggregation) rather than pathogenic 
(pro-aggregation) effect [149]. C-terminal fragmentation at D219 produced a protein more prone to 
phosphorylation at S409/S410 [145], and similarly, acetylation at K145 promoted the accumulation of 
TDP-43 aggregates hyperphosphorylated at S409/S410 [144] (Table 5). TDP-43 phosphorylation arose 
primarily at residues clustered within the glycine-rich C-terminus (Figure 5); a protein region 
susceptible to formation of amyloid-like fibrils [150,151]. 
Table 5. Summary of TDP-43 PTMs and propensity for protein aggregation. 
Post-
Translational 
Modification 
Residues 
Modified 
Author & 
Year 
Aggregation 
Formation 
of 
Oligomers 
Formation 
of Fibrillar 
Aggregates 
Formation of 
Amorphous 
Aggregates 
Acetylation K145 
Wang et 
al., 2017 
[143] 
Increase - - - 
 K145, K192 
Cohen et 
al., 2015 
[144] 
Increase - - - 
C-terminal 
fragmentation 
D89, D219 
Zhang et 
al., 2009 
[145] 
Increase - - - 
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Phosphorylation 
S379, S403, 
S404, S409, 
S410, 
S403/S404, 
S409/S410, 
S379/S403/
S404, 
S379/S409/
S410, 
S403/S404/
S409/S410 
Li et al., 
2011 [149] Decrease - - - 
 S409/S410 
Carlomagn
o et al., 
2014 [146] 
Increase - Increase - 
 
S379, 
S403/404, 
S409, S410, 
S409/S410 
Hasegawa 
et al., 2008 
[147] 
Increase Increase Increase - 
 S409/S410 
Brady et 
al., 2011 
[148] 
Decrease - - - 
 
Figure 5. Schematic representation of TDP-43 illustrating PTMs and respective amino acid residues. 
3.3.2. SOD1 PTMs and Propensity for Aggregation 
The agent employed for acetylation of SOD1 in vitro as well as the site(s) of acetylation 
influenced the type of aggregates formed [152]. SUMOylation at K75 increased aggregation of mutant 
(and wild-type) SOD1 [153,154] (Table 6 and Figure 6). 
Table 6. Summary of SOD1 PTMs and propensity for protein aggregation. 
Post-
Translational 
Modification 
Residues 
Modified 
Author & 
Year Aggregation 
Formation 
of 
Oligomers 
Formation of 
Fibrillar 
Aggregates 
Formation of 
Amorphous 
Aggregates 
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Acetylation 
K23/K30/K36/H4
6/K91/K122/K12
8/K136 (BP *) 
Rasouli et al., 
2017 [152] - - Decrease - 
 K36/K128 (BT *) Rasouli et al., 2017 [152] - - Decrease Increase 
 
K23/S25/K30/K3
6/K91/K122/K12
8/K136 (PM *) 
Rasouli et al., 
2017 [152] - - Decrease Increase 
 K9 (CA*) Rasouli et al., 2017 [152] - - Increase - 
 
K9/K23/K30/K36
/K91/K122/K136/
T54/S68 (GA *) 
Rasouli et al., 
2017 [152] - - Decrease Increase 
 
K23/S25/K30/K3
6/K122/K128/K1
36 (SA *) 
Rasouli et al., 
2017 [152] - - Increase - 
SUMOylation K75 (SUMO3) † Niikura et al., 2014 [153] Increase - - - 
 K75 (SUMO1) ‡ Fei et al., 2006 [154] Increase - - - 
* Abbreviations: BP, 3,3’,4,4’-biphenyltetracarboxylic dianhydride; BT, benzophenone-3,3’,4,4’-
tetracarboxylic dianhydride; PM, pyromellitic dianhydride; CA, citraconic anhydride; GA, glutaric 
anhydride; SA, succinic anhydride. † Mutant SOD-1 was used in this study. ‡ Wild-type and mutant 
SOD-1 were used in this study. 
 
Figure 6. Schematic representation of SOD1 illustrating PTMs and respective amino acid residues. * 
Due to their importance for SOD1 structural stability, metal-binding sites, and residues involved in 
disulphide bond formation are also marked. 
3.4. Huntington’s Disease 
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Acetylation of Htt decreased the formation aggregated fibrils [155]. Htt phosphorylation at T3 
decreased Htt aggregation [156–158], as did phosphorylation at S13 and/or S16 [159,160]. Proteolytic 
cleavage of mutant Htt generated fragments with an increased tendency to aggregate into nuclear 
and cytoplasmic inclusion bodies [161] (Table 7). Residues targeted by acetylation, phosphorylation, 
or proteolytic cleavage were confined to the N-terminal region and polyQ stretch of Htt (Figure 7); 
regions that play a critical role in Htt aggregation behaviour [161,162]. 
Table 7. Summary of huntingtin PTMs and propensity for protein aggregation. 
Post-Translational 
Modification 
Residues 
Modified 
Author & 
Year Aggregation 
Formation 
of 
Oligomers 
Formation of 
Fibrillar 
Aggregates 
Formation of 
Amorphous 
Aggregates 
Acetylation K6, K9, K15 ‡ 
Chaibva et 
al., 2016 
[155] 
Decrease  Decrease - 
Phosphorylation T3 * Chiki et al., 2017 [156] Decrease - Decrease - 
 T3 
Ansaloni et 
al., 2014 
[157] 
Decrease Decrease Decrease - 
 T3 * 
Cariulo et 
al., 2017 
[158] 
Decrease - - - 
 S13, S16, S13/S16 † 
DeGuire et 
al., 2018 
[159] 
Decrease Increase Decrease - 
Pseudo-
phosphorylation S13, S16 
† 
DeGuire et 
al., 2018 
[159] 
Decrease Increase Decrease - 
 S13/S16 * Gu et al., 2009 [160] Decrease - Decrease - 
Proteolytic 
Cleavage 
Cleavage site 
between 
residue 104 
and 114 * 
Lunkes et 
al., 2002 
[161] 
Increase - - - 
* Mutant huntingtin protein was used in this study. † Wild-type and mutant huntingtin protein were 
used in this study. ‡ Wild-type and truncated huntingtin protein were used in this study. 
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Figure 7. Schematic representation of huntingtin illustrating PTMs and respective amino acid 
residues. 
3.5. Spinocerebellar Ataxias 
3.5.1. Ataxins 
SUMOylation of ataxin-1 (across the whole protein) enhanced aggregation [163], as did 
proteolytic cleavage of ataxin-3 [164] (Table 8). Since SUMOylation of ataxin-1 was not confined to a 
specific amino acid residue, a schematic representation was only produced for ataxin-3. The 
proteolytic cleavage site was mapped to the second ubiquitin-interacting motif domain of the protein 
(Figure 8). 
Table 8. Summary of ataxins PTMs and propensity for protein aggregation. 
Post-
Translational 
Modification 
Residues 
modified 
Author & 
Year Aggregation 
Formation of 
Oligomers 
Formation of 
Fibrillar 
Aggregates 
Formation of 
Amorphous 
Aggregates 
SUMOylation 
(ataxin-1) 
Multiple 
residues 
Ryu et al., 
2010 [163] Increase - - - 
Proteolytic 
Cleavage (ataxin-
3) 
N-terminal 
region cleavage 
near residue 
250 
Haacke et 
al., 2006 
[164] 
Increase - - - 
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Figure 8. Schematic representation of ataxin-3 illustrating PTMs and respective amino acid residues. 
3.6. Transmissible spongiform encephalopathies: 
3.6.1. Prion Protein 
Oxidation and nitration at multiple residues of PrPc increased aggregation propensity with 
enhanced formation of fibrillar as well as amorphous aggregates [165]. Phosphorylation at S43 of PrPc 
enhanced its aggregation, with a tendency of the phosphorylated form to produce large fibrillar and 
fewer amorphous aggregates than unmodified PrPc [166] (Table 9). PrPc residues susceptible to 
nitrative and oxidative modifications were primarily clustered within the folded C-terminal domain 
of the protein (Figure 9).  
Table 9. Summary of PrPc PTMs and propensity for protein aggregation. 
Post-
Translational 
Modification 
Residues 
Modified Author & Year Aggregation 
Formation 
of 
Oligomers 
Formation of 
Fibrillar 
Aggregates 
Formation of 
Amorphous 
Aggregates 
Oxidative 
modification and 
Nitration 
Oxidation: W34, 
W60, M157, 
M209, M216, 
C217, 
M132/M137 
Dear et al., 
2007 [165] Increase - Increase Increase 
 
Nitration: Y41, 
Y41/Y52, Y131, 
Y148, Y152, 
Y153, Y158, 
Y221, Y227/Y228 
 Increase - Increase Increase 
Phosphorylation S43 
Giannopoulos 
et al., 2009 
[166] 
Increase - Increase Decrease 
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Figure 9. Schematic representation of PrPc illustrating PTMs and respective amino acid residues. 
3.7. Multiple sclerosis: 
Bsn: Bsn protein was identified only recently as a protein aggregate that may contribute to 
neurotoxicity in MS [12], and an examination of the influence of PTMs upon Bsn aggregation has yet 
to be undertaken. 
Aβ and tau: The detection of oligomeric aggregates of Aβ and tau, and APP within brain tissue 
from MS patients [8,13] suggests that for some NDDs, a common subset of potentially toxic protein 
accumulations exist. The PTMs that influence protein aggregation of Aβ and tau, are detailed in 
Tables 2 and 3, respectively, and Figures 2 and 3, respectively. Whether similar PTMs are relevant to 
the Aβ and tau deposited in brain tissue of MS patients has yet to be determined. 
4. Discussion: 
This review considered PTMs that may influence pathogenic protein aggregation in NDDs. 
Evidence indicating a role for PTMs in a NDD tended to reflect the prevalence of the disease: with 
most studies focused upon AD or PD, with relatively sparse literature coverage of PTMs in SCAs or 
TSEs, and no studies identified that investigated the PTM of Bsn protein in MS. Furthermore, for 
many of the studies of the PTMs, only a single report of the effect of the PTM has been published. 
However, for some of the PTMs, at least two independent studies have considered aggregation 
behaviour in response to a PTM at the same amino acid, and these have been discussed further: 
Aβ isoaspartate: Results from Table 2 indicate that isoaspartate formation has a pro-aggregation 
effect on Aβ. Consistent with a role for this PTM in AD, the levels of isoaspartate in Aβ was 
significantly higher in brain tissue from patients with AD compared with age-matched controls [167]. 
Isoaspartate is a non-enzymatic PTM that forms in peptides or proteins from asparagine deamination 
or aspartic acid isomerisation [168,169]. Isoaspartate formation influences protein structure and 
function since it results in a kink in the peptide backbone and the addition of a methylene group. 
Protein levels of isoaspartate are normally restricted in vivo via the action of the enzyme, protein L-
isoaspartyl methyltransferase (PIMT) [168,169]. However, for peptides or proteins that become 
extracellular, including Aβ, inaccessibility to cytosolic or nuclear PIMT activity renders them 
susceptible to ongoing isoaspartate formation. A therapeutic intervention that prevents the formation 
of isoaspartate within Aβ and thereby limits its pro-aggregation effect may be of benefit in AD, 
perhaps through targeted repair of Aβ or increased activity of PIMT.   
Aβ phosphorylation: The results of Table 2 suggest that there are divergent effects of 
phosphorylation on Aβ aggregation; such that phosphorylation of S8 stimulated Aβ aggregation, 
whereas phosphorylation at S26 decreased aggregation. Hence, total phosphorylation of Aβ is 
unlikely to be an informative marker of aggregation propensity and toxicity. Moreover, site-specific 
phosphorylation may need to be considered for therapeutic interventions: agents that, for example, 
enhance phosphatase activity or inhibit kinase activity at S8, or conversely inhibit phosphatase 
activity and promote kinase activity at S26 may be useful for limiting pathogenic aggregation. 
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Tau phosphorylation: Although hyperphosphorylation of tau as a trigger for the formation of 
NFTs and progression of AD has been reported [170], evidence collated in this review suggests that 
tau phosphorylation and aggregation is only specific to certain tau isoforms (Table 3). Indeed, 
phosphorylation of the tau isoforms 4R0N and 3R2N resulted in decreased tau aggregation [114]. By 
contrast, phosphorylation or pseudo-phosphorylation of the longest tau isoform, 4R2N, increased tau 
aggregation [114,116,117]. Clinical treatments for AD that have utilised kinase inhibitors to prevent 
tau hyperphosphorylation and aggregation have had limited success [171], and future studies will 
need to consider those tau isoforms that exhibit increased propensity to aggregate after 
phosphorylation, as well as the influence of site-specific phosphorylations. 
α-synuclein acetylation: Four of five studies reported reduced aggregation of α-synuclein after 
acetylation within the N-terminal region (Table 4). Acetylation of α-synuclein interferes with internal 
hydrogen-bonding and induces an α-helical rather than β-pleated sheet structure, and this may be 
the mechanism for decreased aggregation [124,125]. In contrast, a single study reported increased α-
synuclein aggregation after acetylation [127]. Hence, collectively, there may be a beneficial 
therapeutic anti-aggregation effect upon α-synuclein through targeted N-terminal acetylation. 
α-synuclein 4-hydroxy-2-neonal (HNE) modification: NDDs are associated with cellular redox 
stress that can lead to increased lipid peroxidation and formation of the α,β-unsaturated 
hydroxyalkenal, HNE, capable of covalently adducting α-synuclein [133]. Adduction of α-synuclein 
by HNE reduced the tendency of α-synuclein to undergo fibrillar aggregation (Table 4) [131,133]. 
However, whether this could be exploited as a protective modification is equivocal, since HNE 
modification decreased aggregation by stabilising oligomeric intermediates, and α-synuclein 
oligomers may also be toxic to neurons [172,173]. 
α-synuclein O-GlcNAcylation: Protein glycosylation as O-GlcNAcylation arises from 
enzymatic O-linked addition of β-N-acetyl-glucosamine at serine or threonine residues and is 
involved in a number of homeostatic mechanisms. All three studies undertaken to date reported 
decreased α-synuclein aggregation after O-GlcNAcylation [134–136]. Furthermore, interplay 
between PTMs was reported, with an inhibitory effect of α-synuclein T72 O-GlcNAcylation upon α-
synuclein S129 phosphorylation [136]; a PTM that normally enhances α-synuclein aggregation and 
promotes neuropathology [137,138]. Collectively, these studies suggest a benefit of O-GlcNAcylation 
that could be manipulated by therapeutic intervention. However, total levels of O-GlcNAcylation 
were increased in post-mortem tissue from three PD patients compared to control subjects, although 
specific levels of O-GlcNAcylation of α-synuclein were not determined [174].  
α-synuclein phosphorylation: Phosphorylation at S129 of α-synuclein has a pro-aggregation 
effect, is detected in LBs, and is associated with proteinopathy in PD [137,138,174]. Hence, there may 
be therapeutic value in manipulating the levels of this phosphorylation. To that end, a transgenic 
mouse model of α-synucleinopathy with enhanced dephosphorylation at S129 displayed reduced 
aggregation and symptomatic improvement [91].  
TDP-43 acetylation: Acetylated TDP-43 has been recovered within spinal cord of patients with 
ALS [144], indicative of its pathological relevance. In support of this supposition, two studies 
demonstrated enhanced aggregation of TDP-43 following its acetylation (Table 5). Since the 
acetylated residues (K145 and K192) are within the nucleic acid binding regions (Figure 5), this PTM 
may reduce RNA-binding of TDP-43 and promote the accumulation of dysfunctional TDP-43 
aggregates [144]. Thus, preventing TDP-43 acetylation may provide a new approach for treatment of 
ALS. 
Superoxide Dismutase 1 SUMOylation: SUMOylation of mutant or wild-type SOD1 by SUMO1 
and SUMO3 at K75 enhanced its aggregation [153,154]. Thus, preventing SUMOylation of SOD1 may 
be beneficial to limit progression of fALS. Certainly, inhibition of mutant SOD1 SUMOylation at K75 
has proven a successful approach to prevent SOD1 aggregation in neuronal cells [175], and therefore 
underpins a rationale for translation to animal models. 
Huntingtin phosphorylation: Preclinical models of HD and HD patient brain samples display 
lower phosphorylation levels at T3 of huntingtin compared with controls [158]. Htt phosphorylation 
at T3 as well as at S13/16 inhibits the formation of aggregates, potentially serving as a protective 
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mechanism against proteinopathic changes (Table 7). Consistent with this proposal, restored N-
terminal Htt phosphorylation reversed neurotoxicity in a model of HD [176]. Therefore, modification 
of the levels of Htt phosphorylation represent a promising target for therapeutic development. 
Additionally, Htt phosphorylation at T3 prevents phosphorylation at S13/S16 [177]. Nevertheless, 
since both phosphorylation at T3 and S13/S16 decrease Htt aggregation, it will be of interest to 
delineate their potential cumulative effects upon Htt aggregation.  
A summary of the PTMs whose manipulations may be of therapeutic benefit are included in 
Table 10. 
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Table 10. Summary of PTMs with therapeutic potential and suggested pharmacological interventions. 
Protein PTM Residues Schematic Representation of Modification 
Suggested 
Pharmacological 
Intervention 
Aβ 
Isoaspartate 
modification 
D1, D7, D23 
 
Inhibition 
Aβ Phosphorylation S8 
 
Inhibition 
Aβ Phosphorylation S26 
 
Enhancement 
αS Acetylation 
K6, K10, N-
terminal 
region 
 
Enhancement  
αS 
HNE 
modification 
H50 
 
Inhibition 
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αS O-GlcNacylation 
T72, T75, T81, 
S87 
 
Enhancement 
αS Phosphorylation S129 
 
Inhibition 
TDP-43 Acetylation K145, K192 
 
Inhibition 
SOD1 SUMOylation K75 
 
Inhibition 
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HTT Phosphorylation T3, S13, S16 
 
Enhancement 
Abbreviations: αS, α-synuclein. 
 
Brain Sci. 2020, 10, 232 28 of 37 
 
4.1. Study Limitations: 
The majority of studies investigating the roles of PTMs for proteins that contribute to NDDs 
have been undertaken in vitro, and it is therefore difficult to make direct inferences to in vivo effects. 
Furthermore, while we have compiled and summarised the primary literature that has examined the 
effects of PTMs upon protein aggregation, these studies invariably only consider individual PTMs, 
and therefore will not reflect the multiple PTMs experienced within a dynamic in vivo system. Hence, 
analysis of site-specific PTMs by, for example, mass spectrometric means, only provides a snapshot 
of site occupancy at that juncture. Indeed, PTMs co-exist in vivo and may act in a permissive, 
reciprocal, antagonising, potentiating, or even synergistic manner to influence overall protein 
structure and function. Additionally, to consider functional relevance of each PTM to support 
therapeutic targeting, it is also important to consider the stoichiometry associated with each PTM, 
and this has not yet been addressed in most of the in vitro or in vivo studies.  
Our study has also only focussed upon the influence of the PTM upon protein aggregation, and 
for which measurements of aggregation were conducted by different means. The majority of studies 
have utilised ThT fluorescent assays, but other protein separation and imaging systems were also 
used–refer to Supplementary Data, S2. Furthermore, differences between biological models, protein 
sources (for example, synthetic or recombinant peptides or proteins), and assay techniques, could 
account for some of the conflicting studies that describe the effects of PTMs on aggregation 
behaviour. Furthermore, we have tried to consider different aggregation elements: oligomers, 
fibrillary, and amorphous aggregates, but some studies have demonstrated reduced aggregate 
formation via increased stability of oligomeric species. Hence, one must interpret results with caution 
due to the unresolved debate as to whether oligomers and/or mature aggregates are the primary toxic 
species [178]. While both oligomers and larger aggregates are known to adopt β-sheet conformations, 
Aβ and α-synuclein oligomers can be arranged in antiparallel β-pleated sheets, whereas fibrillar 
aggregates display a parallel β-sheet structure [179,180]. Hence, differences in secondary structures, 
certainly for Aβ, may ultimately influence neurotoxicity [181]. Lastly, the formation of toxic 
oligomers or aggregates may not only be a consequence of increased protein aggregation propensity, 
but also arise from dysfunctional protein degradation pathways.  
4.2. Summary and Conclusions 
A more comprehensive understanding of the molecular mechanisms that trigger pathogenesis 
or progression of NDDs is a prerequisite to developing new treatment options. The results of this 
review highlight that multiple PTMs can alter aggregation potential and thereby contribute to 
proteinopathies. The future development of therapies to modify PTM profiles for key NDD-related 
proteins may provide an as yet untapped source of novel drug treatments for NDDs.  
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